Followers | 1 |
Posts | 357 |
Boards Moderated | 0 |
Alias Born | 03/14/2008 |
Thursday, June 26, 2014 4:42:29 AM
July 31 Halozyme FDA Advisory Panel
Halozyme Therapeutics (HALO) will face an FDA advisory panel on July 31. This panel will be over Halozyme's drug HyQvia, and will make a recommendation on whether or not the FDA should approve the drug for commercial sale in the United States. It is important to note, however, that the panel vote is nonbinding, so the FDA is in no way bound to follow the advice of its panels. Still, the FDA very rarely overrules the advice of its panels, so this will be a crucial step for Halozyme.
Halozyme is attempting to obtain approval for HyQvia as a primary replacement therapy in patients with primary immunodeficiency. If approved, this drug would add to Halozyme's growing drug portfolio and add another revenue pathway for the company. Halozyme needs this revenue, as the company lost $26.5 million last quarter on $12 million in revenue. The product is partnered with Baxter International (BAX), and is approved for use in multiple European countries. Should HyQvia obtain FDA approval, it would allow for Halozyme to obtain much needed revenue in order to continue advancing the other parts of its development pipeline. Halozyme is entitled to mid-single digit royalties on net sales of the drug. HyQvia is already approved in a variety of European countries which, although the FDA is not bound to follow the decisions of other countries, should help to make investors confident in the approvability of HyQvia. We are not exactly sure of the approval date for HyQvia after the FDA panel. I project the PDUFA date to be August 21, 2014, as the letter was dated 5/21/2014 announcing that the FDA was choosing to extend the drug review time. The typical extension time is a three-month extension, which is how I arrived at the August 21, 2014 PDUFA date. This decision will be important to both Halozyme and Baxter moving forward, as it has the potential to provide both companies with significant revenue. Investors should get a good idea of how the FDA views the treatment through the briefing documents released before the panel, and a panel vote in favor of HyQvia should go a long way towards obtaining FDA approval for the drug. I do expect a slight run-up in share price before the FDA advisory panel, as this decision will be very important to Halozyme shareholders. However, in my opinion after the panel's decision we will not likely see a large run-up due to the fact that approval or denial will likely be baked into the share price of the stock at that point.
Recent HALO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 10:49:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:01:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:03:48 PM
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis • PR Newswire (US) • 09/13/2024 05:30:00 PM
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer • PR Newswire (US) • 09/13/2024 12:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:56:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:12:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:05:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:16:18 PM
- Halozyme to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 11:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:03:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:11:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 08:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:59:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:31:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:57:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:08:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:19:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:03:09 PM
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:48:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 08:05:48 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM